Physician profile
Katherine E Pinto
NPI 1356189856
$670.56
in general payments reported to CMS, 2019-2025
20 companies · $585 in 2025
The $585 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $85.76 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $85.76 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $78.80 | 2025 | Airsupra |
| Exact Sciences Corporation | $50.63 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $44.38 | 2025 | |
| Edwards Lifesciences Corporation | $42.86 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Aimmune Therapeutics, INC. | $42.09 | 2025 | Zenpep |
| Xeris Pharmaceuticals, INC. | $40.10 | 2025 | Gvoke Hypopen, Keveyis |
| Boston Scientific Corporation | $35.56 | 2025 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $27.26 | 2025 | |
| Abiomed | $27.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.90 | 2025 | Trintellix |
| Ibsa Pharma INC. | $22.35 | 2025 | Flector, Licart, Tirosint |
| Sanofi-Aventis U.S. LLC | $22.32 | 2025 | |
| Sanofi Pasteur INC. | $21.58 | 2025 | |
| Medtronic, INC. | $20.73 | 2025 | Symplicity G3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.63 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $18.17 | 2025 | Rexulti |
| Lilly USA, LLC | $16.78 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $14.51 | 2025 | Repatha, Otezla |
| Novo Nordisk INC | $14.15 | 2025 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.